StockNews.AI
ALT
StockNews.AI
53 days

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT

1. Pomerantz LLP is investigating Altimmune for potential securities fraud. 2. Investors may be impacted by claims against Altimmune's officers and directors. 3. Altimmune's stock fell 53.18% after revealing trial results. 4. The trial results for pemvidutide lacked statistically significant improvement. 5. The investigation may lead to a class action lawsuit affecting ALT's stock.

5m saved
Insight
Article

FAQ

Why Very Bearish?

The significant drop in stock price indicates investor distrust following trial results and potential fraud claims. Similar cases in the past, such as with Valeant Pharmaceuticals, caused severe long-term value destruction due to fraud accusations.

How important is it?

The potential for a class action lawsuit directly affects investor sentiment and stock valuation, making the situation highly significant. The ongoing investigation alone is likely to keep ALT in the spotlight for adverse news.

Why Short Term?

Immediate investor panic can lead to further price decline, while longer-term impacts will depend on investigation results and management's response. Historical responses to similar lawsuits typically show short-term stock volatility.

Related Companies

VALNCRISPTLA
, /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Altimmune and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On June 26, 2025, Altimmune issued a press release announcing "topline results from the IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH)." Although Altimmune described the results as "positive," the press release reported that "[t]he effects on fibrosis improvement without worsening of MASH in an ITT analysis"—a key efficacy endpoint—"were 31.8% and 34.5% for pemvidutide 1.2 mg and 1.8 mg, respectively compared with 25.9% for placebo (differences not statistically significant)."  On this news, Altimmune's stock price fell $4.10 per share, or 53.18%, to close at $3.61 per share on June 26, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT: Danielle Peyton Pomerantz LLP [email protected] 646-581-9980 ext. 7980 SOURCE Pomerantz LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News